Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00262925 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00262925: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00262925 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00262925, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving combination chemotherapy together with alemtuzumab works in treating patients with relapsed or refractory acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving combination chemotherapy together with alemtuzumab may kill more cancer cells.
Interventions
- DRUG dexamethasone
- DRUG leucovorin calcium
- BIOLOGICAL alemtuzumab
- DRUG methotrexate
- DRUG asparaginase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-06 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00262925
The ClinicalTrials.gov registry entry for NCT00262925 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which dexamethasone is the first listed.
NCT00262925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00262925 about?
NCT00262925 is a clinical study titled "Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia". This phase II trial is studying how well giving combination chemotherapy together with alemtuzumab works in treating patients with relapsed or refractory acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or...
What is the current status of trial NCT00262925?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2006-06. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00262925?
The interventions under investigation include: dexamethasone (DRUG), leucovorin calcium (DRUG), alemtuzumab (BIOLOGICAL), methotrexate (DRUG), asparaginase (DRUG).
Who is sponsoring clinical trial NCT00262925?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.